Semaglutide may be appropriate if: You have kidney disease, metabolic associated steatohepatitis (fatty liver) or cardiovascular disease
A new systematic review published in the journal eClinicalMedicine on Wednesday examined 48 studies that analyzed and predicted the outcomes of people who either had diabetes or were overweight or obese and took popular GLP-1 medications such as liraglutide (under brand names such as Victoza and Saxenda), semaglutide (under brand names such as Ozempic, Wegovy, Rybelsus) and tirzepatide (under brand names like Mounjaro and Zepbound)
Another comprehensive meta-analysis revealed significant reductions in hospitalization for heart failure (76% reduction, relative risk 0.24), death from cardiovascular causes (17% reduction), coronary revascularization (24% reduction), and all-cause mortality (21% reduction)
Potential Side Effects: Navigating Overall Health Risks While taking Ozempic or taking Wegovy offers metabolic advantages, the medication affects everyone differently
If youre thriving on your medication but dread the needle, there may be a way to space things outsafely, strategically, and under supervision
